Fusion Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Fusion Pharmaceuticals Inc (FUSN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Fusion Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 486,127M combined for tracked competitors (0.0% combined share).
- Peer differentiation: Revenue per employee of $0.03M compares with $1.08M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Fusion Pharmaceuticals Inc vs. its Competitors, Q1 2024
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Fusion Pharmaceuticals Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Fusion Pharmaceuticals Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Fusion Pharmaceuticals Inc's competitor groups requires a Commercial License.
Fusion Pharmaceuticals Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Fusion Pharmaceuticals Inc | - | - | - | Yes |
| Competitors combined (49) | ||||
| High-Confidence Competitors (8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
FUSN Stock Performance relative to its Competitors
FUSN Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 2 | Revolution Medicines Inc | 282.9% | Outperformed |
| 3 | Cullinan Therapeutics Inc | 282.9% | Outperformed |
| 4 | Kymera Therapeutics Inc | 282.9% | Outperformed |
| 5 | Quince Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Fusion Pharmaceuticals Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Fusion Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Fusion Pharmaceuticals Inc | 1,805.37 | 0.90 |
| Eli Lilly And Company | 1,027,620.95 | 79,665.80 |
| Merck and Co Inc | 355,210.70 | 66,569.00 |
| Novartis Ag | 275,752.75 | 56,674.00 |
| Astrazeneca Plc | 246,327.40 | 58,739.00 |
| Amgen Inc | 221,554.88 | 38,095.00 |
| SUBTOTAL | 2,988,660.25 | 488,428.46 |
Sign in to see all competitors of Fusion Pharmaceuticals Inc .
Sources: Fusion Pharmaceuticals Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Fusion Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Fusion Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Qsam Biosciences Inc | Named by the company | 85% |
| Actinium Pharmaceuticals, Inc. | Named by the company | 85% |
| Ipsen S.A. | Named by the company | 85% |
| RadioMedix, Inc | Named by the company | 85% |
| Clovis Oncology, Inc. | Named by the company | 85% |
| Orano Med | Named by the company | 85% |
| Y-mAbs Therapeutics, Inc. | Named by the company | 85% |
| Johnson & Johnson | Named by the company | 85% |
| RayzeBio, Inc. | Named by the company | 85% |
| Curie Therapeutics, Inc. | Named by the company | 85% |
| POINT Biopharma Inc. | Named by the company | 85% |
| Bayer AG | Named by the company | 85% |
| Novartis AG | Named by the company | 85% |
| Telix Pharmaceuticals Limited | Named by the company | 85% |
| Pfizer Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Fusion Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Fusion Pharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Fusion Pharmaceuticals Inc .
Fusion Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Fusion Pharmaceuticals Inc | 1,805 | 33,481 | -3,862,074 |
| Eli Lilly And Company | 1,027,621 | 1,593,316 | 534,224 |
| Merck and Co Inc | 355,211 | 887,587 | 42,267 |
| Novartis Ag | 275,753 | 752,973 | 185,566 |
| Astrazeneca Plc | 246,327 | 706,847 | 123,141 |
| Amgen Inc | 221,555 | 2,930,385 | 672,538 |
| PEERS TOTAL | 2,986,855 | 1,077,365 | 173,824 |
Sign in to see all peers for Fusion Pharmaceuticals Inc .
Fusion Pharmaceuticals Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
| Pfizer Inc | United States 58.91 % |
| Vertex Pharmaceuticals Inc | United States 61.68 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Fusion Pharmaceuticals Inc .
Fusion Pharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (95 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.7x | - |
| EV / EBITDA | - | 21.3x | - |
| P/B | 6.2x | 5.1x | +1.1x |
| Return on Equity | -48.74 % | industry aggregate | -38.24 % |
| Return on Invested Capital | -23.01 % | -5.98 % (avg) | -17.03 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Fusion Pharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenue Growth | - | - | - | 41.55 % |
| Operating Margin | - | - | -6,025.60 % | -4,798.45 % |
| Return on Invested Capital | - | -15.78 % | -21.60 % | -21.79 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Fusion Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 38.2 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 10.0% median pace.
- A meaningful share of tracked competitors (38.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-39.0% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Fusion Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Fusion Pharmaceuticals Inc | 2.07 | 12.24 | 0.20 |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
Sign in to see all peers for Fusion Pharmaceuticals Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Fusion Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Fusion Pharmaceuticals Inc | Q1 2024 | - | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| PEERS TOTAL | +11.5 % | -30.9 % |
Sign in to see all peers for Fusion Pharmaceuticals Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Fusion Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Fusion Pharmaceuticals Inc | Q1 2024 | - | +9.1 % |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
Sign in to see all peers for Fusion Pharmaceuticals Inc .
Fusion Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Fusion Pharmaceuticals Inc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
Sign in to see all peers for Fusion Pharmaceuticals Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Fusion Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Fusion Pharmaceuticals Inc | - | 1,997.09 |
| Eli Lilly And Company | 38.60 | 12.90 |
| Merck and Co Inc | 115.98 | 5.34 |
| Novartis Ag | 19.72 | 4.87 |
| Astrazeneca Plc | 24.09 | 4.19 |
| Amgen Inc | 25.30 | 5.82 |
| PEERS AVERAGE | 37.98 | 6.12 |
Sign in to see all peers for Fusion Pharmaceuticals Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.